Clinical Trial Update: Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing Aumolertinib to Osimertinib as first-line therapy for EGFR-mutated locally advanced or metastatic non-small cell lung cancer; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Aumolertinib (Aumolertinib)
• Osimertinib (osimertinib)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING